Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Harrow (Nasdaq:HROW) and Samsung Bioepis announced the US relaunch of BYOOVIZ (ranibizumab-nuna), an interchangeable biosimilar to Lucentis, under a commercialization partnership. Samsung Bioepis handles development, regulatory registration, and manufacturing, while Harrow leads US commercialization of both BYOOVIZ and OPUVIZ (aflibercept-yszy).
BYOOVIZ is FDA-approved and interchangeable for treating wet AMD, macular edema following RVO, and mCNV. OPUVIZ, interchangeable to Eylea, is indicated for wet AMD, RVO-related macular edema, DME, and DR.
Harrow (Nasdaq:HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved, interchangeable biosimilar referencing LUCENTIS for Wet AMD, RVO-related macular edema, and mCNV.
Harrow holds exclusive U.S. commercialization rights to BYOOVIZ and OPUVIZ, expanding its retina portfolio alongside IHEEZO and TRIESENCE in a roughly $9 billion U.S. anti-VEGF market.
Harrow (Nasdaq:HROW) announced the re-launch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, indicated for all forms of vernal keratoconjunctivitis (VKC) in children and adults.
The topical calcineurin inhibitor targets underlying VKC inflammation, showed statistically significant trial results, and is backed by physician education, access, and affordability programs to improve long-term pediatric eyecare.
Harrow (Nasdaq:HROW) announced that management will present at William Blair’s 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.
The presentation will be webcast live on Harrow’s website, with a replay available for about 90 days.
Harrow (Nasdaq:HROW) reported first quarter 2026 revenue of $44.2 million, reduced by an approximate $8 million non-recurring VEVYE gross-to-net adjustment. VEVYE prescriptions hit records and surpassed XIIDRA with about 14% dry eye market share.
Unit demand for IHEEZO rose 18% year-over-year, and TRIESENCE demand increased 136%. Net loss was $27.6 million, or $0.74 per share. Full-year 2026 revenue guidance of $350–$365 million and second-quarter revenue outlook of $71–$81 million were reiterated. Cash and cash equivalents totaled $94.6 million as of March 31, 2026.
Harrow (Nasdaq: HROW) will report first quarter 2026 financial results for the period ended March 31, 2026, on Monday, May 11, 2026 after market close. The company will post a Letter to Stockholders on its Investors page at harrow.com.
Harrow will host a live webcast and conference call at 8:00 a.m. ET on Tuesday, May 12, 2026 to discuss results and provide a business update. Telephone participants must register in advance to receive a unique dial-in number and PIN. A replay of the webcast will be available on the company website for one year.
Harrow (Nasdaq: HROW) announced that IOPIDINE 1% (apraclonidine) received a permanent J-Code J2374, enabling in-office reimbursement effective July 1, 2026. The designation removes a practical barrier to routine office use and is expected to support broader adoption for prophylactic IOP management during ophthalmic laser procedures.
IOPIDINE 1% has shown a reduction in severe post-procedure IOP spikes from ~23% to ~2% (~91% relative reduction). The company highlights a large addressable base—>4 million glaucoma patients and >1.5 million annual ophthalmic laser procedures in the U.S.
Harrow (Nasdaq: HROW) has selected LogiCare3PL as its U.S. distribution partner for Harrow's ophthalmic disease management solutions. Effective Feb 1, 2026, LogiCare3PL will provide both non-title logistics and 3PL title distribution across the U.S., meeting Harrow's rapid onboarding needs.
LogiCare3PL completed Harrow's onboarding in four weeks, supporting faster, cost-effective market access while maintaining high-touch customer engagement and continuity of supply.
Harrow (Nasdaq: HROW) priced a private offering of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due September 15, 2030. The notes will be issued at 100.25% and treated as a single series with an existing $250.0 million 2030 note issue.
The offering is expected to close on March 27, 2026, interest accrues from March 15, 2026, and net proceeds are for general corporate purposes including product development and growth initiatives.
Harrow (Nasdaq: HROW) intends to offer an additional $50.0 million aggregate principal of its 8.625% senior unsecured notes due 2030 as an add-on to the existing $250.0 million series issued Sept 12, 2025.
Proceeds are planned for general corporate purposes, including product launches, development, and strategic opportunities; the offering targets qualified institutional buyers and non-U.S. persons under Regulation S.